XML 46 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW

The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:

 

   

December 31,

2024

    

December 31,

2023

  
Cash   $ 372,695     $ 1,329,016  
Restricted cash     1,424,999       1,409,895  
Total cash and restricted cash   $ 1,797,694     $ 2,738,911  
SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT

 

    Useful Life (in years)  
Computer equipment     5  
Office equipment and furniture     7  
Leasehold improvements     Shorter of the useful life or the lease term  
SCHEDULE OF WARRANT LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

The following reconciles the warrant liabilities for the years ended December 31, 2024 and 2023:

  

                   
    Years ended December 31, 2024 and 2023  
    Series B
warrant liabilities		     Placement
agent warrants		     Total  
Beginning balance, December 31, 2022   $ 6,384,250     $ 48,900     $ 6,433,150  
Unrealized (gain) loss     (5,534,931 )     (48,575 )     (5,583,506 )1
Warrants exercised or transferred     (580,651 )     -       (580,651 )
Ending balance, December 31, 2023     268,668       325       268,993  
Unrealized (gain) loss     (156,000 )     -       (156,000 )
Warrants exercised or exchanged     (112,667 )     -       (112,667 )
Ending balance, December 31, 2024   $ -     $ 325     $ 325  

 

1 Recognition and change in fair value of warrant liabilities per income statement is $5,503,647. The difference of $79,859 is made up of the Warrant issuance costs.
SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE

 

    December 31,
2024		     December 31,
2023		  
Beginning balance – January 1   $ 159,867     $ 2,709,478  
                 
Acquisitions and Settlements     -       (3,260,403 )
                 
Period adjustments:                
Fair value and estimate changes*     47,761       1,716,873  
Earn-out payable in common shares     (17,628)       (159,867  
Earn-out transferred to loans payable, related parties     (190,000)       (846,214  
                 
Ending balance   $ -     $ 159,867  
Less: Current portion     -       (159,867 )
Ending balance, less current portion   $ -     $ -  

 

* Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.
SCHEDULE OF DISAGGREGATION REVENUE

The following table disaggregates the Company’s revenue by line of business, showing commissions earned:

 

Year ended   Medical     Life     Property and Casualty     Total  
                         
December 31, 2024   $ 10,436,750     $ 171,949     $ 3,445,662     $ 14,054,361  
December 31, 2023   $  10,825,064     $ 170,759     $ 2,735,463     $ 13,731,826  
Disaggregates revenue                                
SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS

The following table rolls forward Medigap’s assets and liabilities from their carrying values pre-abandonment to their values post abandonment, and presents the impact of reclassifications, impairments, and write-offs:

 

Medigap Related Assets   Carrying
Value Prior To
Abandonment		     Asset and
Liability
Transfers
Retained by
the Company		     Asset
Impairments
and Liability
Write-Offs		     Carrying
Value as of
December 31, 2023		  
                         
Accounts receivable   $ 56,398     $ -     $ (56,398 )   $          -  
Accounts receivable, related party     3,595       -       (3,595 )     -  
Other receivables     5,388       -       (5,388 )     -  
Current assets – Medigap   $ 65,381     $ -     $ (65,381 )   $ -  
                                 
Property and equipment, net   $ 22,378     $ -     $ (22,378 )   $ -  
Right-of-use assets     119,594       -       (119,594 )     -  
Intangibles, net     4,570,536       (4,258,214 )1     (312,322 )     -  
Goodwill     4,825,634       -       (4,825,634 )     -  
Other assets - Medigap   $ 9,538,142     $ (4,258,214 )   $ (5,279,928 )   $ -  
                                 
Total assets - Medigap   $ 9,603,523     $ (4,258,214 )   $ (5,345,309 )   $ -  
                                 
Accounts payable and other accrued liabilities   $ 4,157     $ -     $ (4,157 )   $ -  
Short term financing agreements     29,500       (29,500 )     -       -  
Chargeback reserve     831,725       -       (831,725 )2     -  
Current portion of leases payable     134,517       -       (134,517 )3     -  
Other liabilities     9,842       -       (9,842 )3     -  
Current liabilities - Medigap   $ 1,009,741     $ (29,500 )   $ (980,241 )   $ -  
                                 
Total liabilities - Medigap   $ 1,009,741     $ (29,500 )   $ (980,241 )   $ -  
                                 
Net assets and liabilities - Medigap   $ 8,593,782     $ (4,228,714 )   $ (4,365,068 )   $ -  

 

  1 Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost. See Note 6, Goodwill and Other Intangible Assets where during fiscal year 2024, the Company subsequently impaired these assets.
   2 Estimated liability write-off per net zero dollar estimated liability value.
  3 Liability discharge pursuant to the Settlement Agreement.

 

 

The following tables disaggregate the major classes of pretax gain and loss as presented in discontinued operations in the consolidated statements of operations.

 

   

Year Ended

December 31,
2024

    

Year Ended

December 31,
2023

  
Income                
Commission income   $                -     $ 744,030  
                 
Expenses                
Commission expense     -       110,639  
Salaries and wages     -       454,663  
General and administrative     -       129,363  
Marketing and advertising     -       426,818  
Depreciation and amortization     -       7,283  
Other expenses (income)     -       (3,902 )
Total discontinued operations expenses before impairments and write-offs     -       1,124,864  
Total discontinued operations income / (loss) before impairments and write-offs   $ -     $ (380,834 )
Gains and (losses) from recoveries and impairments / write-offs of discontinued operations assets and liabilities                
                 
Settlement Recovery, net of costs   $ -     $ 2,761,190  
                 
Asset impairment losses                
Accounts receivable     -       56,398  
Accounts receivable, related parties     -       3,595  
Other receivables     -       5,388  
Property and equipment, net     -       22,378  
Right-of-use assets     -       119,593  
Intangibles, net     -       312,322  
Goodwill     -       4,825,634  
Total asset impairments   $ -     $ 5,345,308  
                 
Liability write-off gains                
Accounts payable and other accrued liabilities     -       4,154  
Other payables     -       9,842  
Chargeback reserve     -       831,725  
Current portion of leases payable     -       134,517  
Total liability write-off gains   $ -     $ 980,238  
                 
Discontinued operations net asset and liability impairments / write-offs gains and (losses)   $ -     $ 4,365,070  
                 
Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities   $ -     $ (1,603,880 )
                 
Loss from discontinued operations before tax   $ -     $ (1,984,714 )
                 
Consolidated statement of operations - Loss from discontinued operations before tax   $ -     $ (1,984,714 )